- Home
- COCH vs PMN Comparison
COCH vs PMN Comparison
Compare COCH & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COCH | PMN |
|---|---|---|
| Founded | 1995 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Blank Checks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 23.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | COCH | PMN |
|---|---|---|
| Price | $0.76 | $14.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $9.50 | ★ $42.67 |
| AVG Volume (30 Days) | 171.5K | ★ 442.7K |
| Earning Date | 03-30-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $208,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $6.27 |
| 52 Week High | $1.91 | $39.75 |
Technical Indicators
Market Signals| Indicator | COCH | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 61.09 | 67.71 |
| Support Level | $0.43 | $8.96 |
| Resistance Level | $0.68 | $17.40 |
| Average True Range (ATR) | 0.08 | 1.94 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 81.46 | 50.96 |
Price Performance
Historical ComparisonAbout COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.